LifeMD is trading 7.2% down at $3.62 as investors position ahead of its Q2 2026 earnings report scheduled for after today’s close.
- The stock had rallied sharply in recent sessions, leading some traders to take profits or de-risk before the results and guidance are disclosed.
- Market participants are closely watching for updates regarding the company's weight-management and telehealth growth outlook.